Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EGRX NASDAQ:RYTM NASDAQ:VNDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEGRXEagle Pharmaceuticals$0.38$0.27$0.00▼$3.87$4.94M0.833,794 shs1,525 shsRYTMRhythm Pharmaceuticals$96.23-0.4%$87.93$55.31▼$122.20$6.59B1.94682,766 shs818,353 shsVNDAVanda Pharmaceuticals$6.39-14.1%$7.57$3.81▼$9.94$447.40M0.651.11 million shs2.25 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEGRXEagle Pharmaceuticals0.00%-20.00%+11.40%+52.00%-80.00%RYTMRhythm Pharmaceuticals-0.39%+18.28%+11.04%-7.12%+49.32%VNDAVanda Pharmaceuticals-14.11%-10.00%-14.23%-15.59%+45.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEGRXEagle Pharmaceuticals$0.38$0.27$0.00▼$3.87$4.94M0.833,794 shs1,525 shsRYTMRhythm Pharmaceuticals$96.23-0.4%$87.93$55.31▼$122.20$6.59B1.94682,766 shs818,353 shsVNDAVanda Pharmaceuticals$6.39-14.1%$7.57$3.81▼$9.94$447.40M0.651.11 million shs2.25 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEGRXEagle Pharmaceuticals0.00%-20.00%+11.40%+52.00%-80.00%RYTMRhythm Pharmaceuticals-0.39%+18.28%+11.04%-7.12%+49.32%VNDAVanda Pharmaceuticals-14.11%-10.00%-14.23%-15.59%+45.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEGRXEagle Pharmaceuticals 0.00N/AN/AN/ARYTMRhythm Pharmaceuticals 2.84Moderate Buy$131.8136.98% UpsideVNDAVanda Pharmaceuticals 2.50Moderate Buy$14.90133.18% UpsideCurrent Analyst Ratings BreakdownLatest VNDA, EGRX, and RYTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026RYTMRhythm Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$140.00 ➝ $143.005/6/2026RYTMRhythm Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$136.00 ➝ $137.005/6/2026RYTMRhythm Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$143.00 ➝ $144.004/21/2026RYTMRhythm Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026VNDAVanda Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/18/2026RYTMRhythm Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$110.00 ➝ $100.003/17/2026RYTMRhythm Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$136.00 ➝ $131.003/17/2026RYTMRhythm Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$140.00 ➝ $130.003/17/2026RYTMRhythm Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$176.00 ➝ $152.003/17/2026RYTMRhythm Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$145.00 ➝ $139.003/17/2026RYTMRhythm Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$139.00 ➝ $130.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEGRXEagle Pharmaceuticals$257.55M0.02$0.95 per share0.40N/A∞RYTMRhythm Pharmaceuticals$189.76M34.75N/AN/A$1.79 per share53.76VNDAVanda Pharmaceuticals$216.10M1.78N/AN/A$5.54 per share1.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEGRXEagle Pharmaceuticals$35.64M$1.180.32N/AN/AN/AN/AN/A5/11/2026 (Estimated)RYTMRhythm Pharmaceuticals-$196.54M-$3.11N/AN/AN/A-93.33%-203.25%-44.99%N/AVNDAVanda Pharmaceuticals-$220.47M-$3.73N/AN/AN/A-109.99%-29.51%-22.02%N/ALatest VNDA, EGRX, and RYTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026VNDAVanda Pharmaceuticals-$0.6880-$0.82-$0.1320-$0.82$54.98 million$51.72 million5/5/2026Q1 2026RYTMRhythm Pharmaceuticals-$0.86-$0.83+$0.03-$0.83$55.78 million$60.11 million2/26/2026Q4 2025RYTMRhythm Pharmaceuticals-$0.79-$0.73+$0.06-$0.73$56.16 million$57.25 million2/11/2026Q4 2025VNDAVanda Pharmaceuticals-$2.18-$2.39-$0.21-$2.39$59.28 million$57.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/AVNDAVanda PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEGRXEagle PharmaceuticalsN/AN/AN/ARYTMRhythm PharmaceuticalsN/A4.174.16VNDAVanda Pharmaceuticals0.012.392.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEGRXEagle Pharmaceuticals85.36%RYTMRhythm PharmaceuticalsN/AVNDAVanda Pharmaceuticals88.14%Insider OwnershipCompanyInsider OwnershipEGRXEagle Pharmaceuticals28.90%RYTMRhythm Pharmaceuticals6.10%VNDAVanda Pharmaceuticals10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataRYTMRhythm Pharmaceuticals14068.53 million64.35 millionOptionableVNDAVanda Pharmaceuticals29060.13 million54.12 millionOptionableVNDA, EGRX, and RYTM HeadlinesRecent News About These CompaniesVanda Pharmaceuticals Bets Big on Growth PipelineMay 7 at 10:32 PM | tipranks.comVanda Pharmaceuticals Announces Participation at May 2026 Investor ConferencesMay 7 at 6:44 PM | prnewswire.comUniversal Beteiligungs und Servicegesellschaft mbH Sells 160,000 Shares of Vanda Pharmaceuticals Inc. $VNDAMay 7 at 8:33 AM | marketbeat.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2026 Earnings Call TranscriptMay 7 at 8:31 AM | insidermonkey.comVanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call TranscriptMay 7 at 6:11 AM | seekingalpha.comVanda Pharmaceuticals Q1 Earnings Call HighlightsMay 7 at 4:17 AM | marketbeat.comVanda (VNDA) Q1 2026 Earnings Call TranscriptMay 7 at 1:23 AM | finance.yahoo.comVanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue EstimatesMay 6 at 6:11 PM | zacks.comVanda Pharmaceuticals (NASDAQ:VNDA) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPSMay 6 at 4:49 PM | marketbeat.comVanda Pharmaceuticals Reports First Quarter 2026 Financial ResultsMay 6 at 4:01 PM | prnewswire.comWall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should KnowMay 5 at 10:55 AM | zacks.comVanda Pharmaceuticals shares rise on Nereus commercial launchMay 5 at 8:50 AM | investing.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by AnalystsMay 5 at 4:11 AM | marketbeat.comVanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 YearsMay 4, 2026 | prnewswire.comVNDA stock rises after hours on commercial launch of motion sickness drugMay 2, 2026 | msn.comAIGH Capital Management LLC Takes Position in Vanda Pharmaceuticals Inc. $VNDAMay 2, 2026 | marketbeat.comVanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 YearsMay 1, 2026 | prnewswire.comVanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026April 29, 2026 | prnewswire.comVanda Pharmaceuticals (VNDA) Expected to Announce Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comVanda Pharmaceuticals (NASDAQ:VNDA) Share Price Crosses Above 200-Day Moving Average - Time to Sell?April 29, 2026 | marketbeat.comVanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM EvidenceApril 28, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVNDA, EGRX, and RYTM Company DescriptionsEagle Pharmaceuticals NASDAQ:EGRX$0.38 0.00 (0.00%) As of 05/6/2026 03:26 PM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Rhythm Pharmaceuticals NASDAQ:RYTM$96.23 -0.38 (-0.39%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$97.02 +0.78 (+0.82%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Vanda Pharmaceuticals NASDAQ:VNDA$6.39 -1.05 (-14.11%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$6.44 +0.06 (+0.86%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally IonQ Just Posted a Breakout Quarter—But 1 Problem Remains Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
